Advanced search
Publication Cover
Clinical Ophthalmology Volume 18, 2024 - Issue
Submit an article Journal homepage
22
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Treatment Outcomes in Patients with Conjunctival Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Yu Matsuo1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0004-0460-8950View further author information
ORCID Icon,
Yu Monden1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanORCID Iconhttps://orcid.org/0000-0001-9027-6948View further author information
ORCID Icon,
Kensuke Sasaki1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanView further author information
,
Hodaka Akune1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanView further author information
,
Shuntaro Ikeda1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanView further author information
,
Daiki Ishio1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanView further author information
,
Kenta Murotani2 Biostatistics Center, Kurume University, Kurume, JapanORCID Iconhttps://orcid.org/0000-0003-0623-9365View further author information
ORCID Icon,
Koji Nagafuji3 Department of Hematology and Oncology, Kurume University School of Medicine, Kurume, JapanView further author information
&
Shigeo Yoshida1 Department of Ophthalmology, Kurume University School of Medicine, Kurume, JapanORCID Iconhttps://orcid.org/0000-0003-1049-8909View further author information
ORCID Icon show all
Pages 1999-2007 | Received 09 Feb 2024, Accepted 11 Jun 2024, Published online: 09 Jul 2024

References

  • Kobayashi Y. JSH practical guidelines for hematological malignancies, 2018. II. Lymphoma-2. Marginal zone lymphoma (MALT lymphoma/extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue and splenic marginal zone lymphoma). Int J Hematol. 2019;110(4):393–405.
  • Sjö LD. Ophthalmic Lymphoma: epidemiology and Pathogenesis. Acta Ophthalmol. 2009;87:1–20. doi:10.1111/j.1755-3768.2008.01478.x
  • Kirkegaard MM, Rasmussen PK, Coupland SE, et al. Conjunctival Lymphoma—An International Multicenter Retrospective Study. JAMA Ophthalmology. 2016;134(4):406–414. doi:10.1001/jamaophthalmol.2015.6122
  • Kirkegaard MM, Coupland SE, Prause JU, Heegaard S. Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 2015;60(5):444–458. doi:10.1016/j.survophthal.2015.05.001
  • Nam SW, Woo KI, Kim YD. Characteristics of primary extranodal marginal zone B-cell lymphoma in Korea: conjunctiva versus other ocular adnexa. Br J Ophthalmol. 2018;102(4):502–508. doi:10.1136/bjophthalmol-2017-310741
  • Saul EE, Alderuccio JP, Reis IM, et al. Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma. Am J Haematol. 2023;98(1):148–158. doi:10.1002/ajh.26591
  • Izutsu K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol. 2019;110(1):11–19. doi:10.1007/s12185-019-02655-5
  • Fung CY, Tarbell NJ, Lucarlli MJ, et al. Ocular Adnexal lymphoma: clinical behavior of distinct world health organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57(5):1382–1391. doi:10.1016/S0360-3016(03)00767-3
  • Shirota N, Nakayama H, Shiraishi S, et al. Target volume dose and clinical outcome in radiotherapy for primary marginal zone lymphoma of the ocular adnexa. Mol Clin Oncol. 2017;6(6):833–838. doi:10.3892/mco.2017.1241
  • Mino T, Mihara K, Yoshida T, Takihara Y, Ichinohe T. Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. Blood Cancer J. 2014;4(9):e245–e245.
  • Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2008;19(2):242–246. doi:10.1093/annonc/mdm457
  • Jeon YW, Yang HJ, Choi BO, et al. Complication of selection and long-term clinical outcomes betweeen chemotherapy and radiotherapy as primary therapeutic modality for ocular adnexal MALT lymphoma. EClin Med. 2018;4-5:32–42. doi:10.1016/j.eclinm.2018.10.001
  • Tanimoto K, Kaneko A, Suzuki S, et al. Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients. Jpn J Clin Oncol. 2007;37(5):337–344. doi:10.1093/jjco/hym031
  • Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81(4):e659–666. doi:10.1016/j.ijrobp.2011.03.050
  • Harada K, Murakami N, Kitaguchi M, et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy. A long-term outcome in 86 patients with 104 treated eyes. Int J Radiat Oncol Biol Phys. 2014;88(3):650–654. doi:10.1016/j.ijrobp.2013.11.235
  • Park HH, Lee WL, Sung SY, Choi BO. Treatment outcome and risk analysis for cataract after radiotherapy of localized ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Radiat Oncol J. 2017;35(3):249–256. doi:10.3857/roj.2017.00374
  • Fukutsu K, Kase S, Ishijima K, et al. The clinical features of radiation cataract in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. Radiat Oncol. 2018;13(1):95. doi:10.1186/s13014-018-1045-7
  • Lee J, Yoon JS, Kim JS, et al. Long-term outcome, relapse patterns, and toxicity after radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma: implications for radiotherapy optimization. Jpn J Clin Oncol. 2019;49(7):664–670. doi:10.1093/jjco/hyz044
  • Nuzzi R, Trossarello M, Bartoncini S, et al. Ocular complications after radiation therapy: an observational study. Clin Ophthalmol. 2020;14:3153–3166. doi:10.2147/OPTH.S263291
  • Annibali O, Chiodi F, Sarlo C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. Biomed Res Int. 2015;2015:895105. doi:10.1155/2015/895105
  • Tuncer S, Tanyildiz B, Basaran M, et al. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: Single institution experience. Curr Eye Res. 2015;40(8):780–785. doi:10.3109/02713683.2014.959605

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.